$699 Million is the total value of Logos Global Management LP's 43 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 34.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $52,768,000 | -24.4% | 800,000 | -40.7% | 7.55% | -7.7% |
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $49,428,000 | -30.2% | 3,600,000 | -7.7% | 7.07% | -14.8% |
| CYTK | Sell | CYTOKINETICS INC | $43,987,500 | -36.0% | 1,250,000 | -16.7% | 6.30% | -21.8% |
| IMVT | Sell | IMMUNOVANT INC | $38,775,000 | -30.7% | 2,500,000 | -20.6% | 5.55% | -15.3% |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $24,168,000 | -17.3% | 950,000 | -5.0% | 3.46% | +1.1% |
| DYN | Sell | DYNE THERAPEUTICS INC | $19,584,000 | -21.4% | 1,700,000 | -20.9% | 2.80% | -4.0% |
| KRTX | Sell | KARUNA THERAPEUTICS INC | $18,164,000 | -38.4% | 100,000 | -33.3% | 2.60% | -24.7% |
| BCYC | Sell | BICYCLE THERAPEUTICS PLCsponsored ads | $15,952,500 | -62.4% | 750,000 | -47.7% | 2.28% | -54.1% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $12,113,000 | -30.4% | 50,000 | -16.7% | 1.73% | -15.0% |
| Sell | DICE THERAPEUTICS INC | $11,746,500 | -43.0% | 410,000 | -37.9% | 1.68% | -30.3% | |
| COGT | Sell | COGENT BIOSCIENCES INC | $10,790,000 | -15.1% | 1,000,000 | -9.1% | 1.54% | +3.6% |
| Sell | VENTYX BIOSCIENCES INC | $9,045,000 | -58.0% | 270,000 | -58.9% | 1.30% | -48.7% | |
| GERN | Sell | GERON CORP | $7,703,500 | -20.4% | 3,550,000 | -11.2% | 1.10% | -2.7% |
| ALXO | Sell | ALX ONCOLOGY HLDGS INC | $6,780,000 | -74.4% | 1,500,000 | -36.2% | 0.97% | -68.7% |
| FGEN | Sell | FIBROGEN INC | $5,598,000 | -33.4% | 300,000 | -42.9% | 0.80% | -18.7% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $3,488,000 | -55.5% | 400,000 | -68.0% | 0.50% | -45.6% |
| Sell | TYRA BIOSCIENCES INC | $1,408,905 | +67.2% | 87,673 | -20.9% | 0.20% | +104.0% | |
| SPRB | Exit | SPRUCE BIOSCIENCES INC | $0 | – | -1,000,000 | -100.0% | -0.13% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.46% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -50,000 | -100.0% | -0.64% | – |
| VERA | Exit | VERA THERAPEUTICS INCcl a | $0 | – | -285,000 | -100.0% | -0.65% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -180,000 | -100.0% | -0.80% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -250,000 | -100.0% | -0.91% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -260,000 | -100.0% | -0.96% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -2,000,000 | -100.0% | -1.71% | – |
| ARQT | Exit | ARCUTIS BIOTHERAPEUTICS INC | $0 | – | -1,400,000 | -100.0% | -2.43% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.